Logo of jester cap with thought bubble.

Image source: The Motley Fool.

R1 RCM Inc. (NASDAQ:RCM)
Q1 2021 Earnings Call
May 4, 2021, 8:00 a.m. ET

Contents:

  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the R1 RCM Q1 2021 Earnings Conference Call. [Operator Instructions]

I would now like to turn the conference over to your speaker today, Mr. Rahim, Head of Investor Relations. Please go ahead, sir.

Atif Rahim -- Senior Vice President, Investor Relations & Business Development

Good morning, everyone, and welcome to the call. Certain statements made during this call may be considered forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In particular, any statements about our future growth, plans and performance, including statements about our strategic and cost-saving initiatives, our liquidity position, our growth opportunities and our future financial performance are forward-looking statements. These statements are often identified by the use of words such as anticipate, believe, estimate, expect, intend, designed, may, plan, project, would and similar expressions or variations. Investors are cautioned not to place undue reliance on such forward-looking statements.

All forward-looking statements made on today's call involve risks and uncertainties. While we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so, except to the extent required by applicable law. Our actual results and outcomes could differ materially from those included in these forward-looking statements as a result of various factors, including, but not limited to the potential impacts of the COVID-19 pandemic and the factors discussed under the heading Risk Factors in our annual report on our latest Form 10-K and in our latest report on Form 10-Q.

We will also be referencing non-GAAP metrics on this call. For a reconciliation of the non-GAAP amounts mentioned to their equivalent GAAP amounts, please refer to our press release.

Now, I'd like to turn the call over to Joe.

Joseph Flanagan -- President & Chief Executive Officer

Thanks, Atif. Good morning, everyone and thank you for joining us. We issued three announcements this morning, which will be the basis for a substantial portion of the agenda on today's call. In addition to Q1 earnings, we announced an agreement to acquire VisitPay, a leader in healthcare and consumer payment solutions that simplify and modernize the payment experience for patients while driving improved financial outcomes for providers. The transaction provides a tax benefit valued at approximately $40 million equating to an effective purchase price of approximately $260 million.

We also announced the strategic expansion of our agreement with Ascension along three broad categories, deployment of our PX solution architecture across ambulatory and acute settings of care, expansion of services performed out in the global shared service centers and expansion of automation use cases across key functions. The new agreement also extends our master services agreement through 2031 effectively a 10-year term.

Let me start with a brief recap of Q1 earnings. I'm pleased to report that 2021 is off to a strong start. Our team continues to execute exceptionally well and we are seeing this manifest itself in the results we're delivering for our customers. First quarter revenue of $342.6 million and adjusted EBITDA of $80.4 million were both ahead of the expectations we communicated on our last earnings call. The upside was driven by higher incentive fees and lower operating costs. While patient volumes in aggregate remain below pre-COVID levels, we have successfully navigated the environment over the past year and believe we are very well positioned to serve our customers and the broader end market in the post-COVID environment.

The tone and quality of discussions with prospective customers in our pipeline is very encouraging. It gives us a high degree of confidence in our goal of signing $4 billion in new end-to-end NPR in 2021. Technology is increasingly becoming the differentiating factor in many decision-making processes. Our patient experience or PX platform is gaining prominence as providers are increasingly incline to make revenue cycle sourcing decisions based on what's best for their patients over and above other criteria.

Additionally, automation presents an opportunity to fundamentally transform the nature of our industry and reduce the heavy reliance on labor that exist today. Our operational control across the entire revenue cycle process provides a unique lens and significant competitive advantage to drive this disruption. These two factors are the driving force behind our continued heavy investment in technology and the strategic rationale for the VisitPay acquisition.

Before I discuss VisitPay in detail, let me provide some background on our PX platform. When we embarked on our PX starting in 2016, we had two important ideas in mind, one, ease the burden on patients when they access healthcare, and two, provide a seamless intuitive journey across all care centers. At the time the strategic potential of a solution subject this was clear, patients are generally highly dissatisfied with their scheduling, billing, and payment experience and any transformation of the patient experience could potentially be a meaningful competitive differentiator for us as well as for our customers.

Fast forward to today. I'm pleased to say we believe we have the most advanced comprehensive technology solution to transform the patient experience. Our PX platform is integrated across care settings ranging from primary care to outpatient settings such as imaging, labs, same day surgery, all the way through to in-patient surgery. With the acquisitions of SCI Solutions and Tonic last year, we significantly enhanced our in-house ability to digitize order intake, scheduling, registration and the authorization process, thereby delivering a robust cost effective digital front-door capability to our customers.

As we deployed our PX solution to customers, we've seen several transformative results, more than 50% of patient registration encounters are performed on a self-service basis, NPS scores are above 75 and we have cut time spent on administrative tasks in half. We've also seen an improvement in collection rates and a decline in the percentage of patient counts that progressed to late-stage collection activities, that are a well publicized dissatisfier for patients. These results have fueled our conviction to continue to invest heavily in PX. The next logical capability to bring it in-house is the technology to modernize the consumer payment ecosystem in healthcare.

VisitPay is a leading consumer payments platform with a proven track record of driving improved payment experience and improved financial outcomes for providers. VisitPay makes the healthcare financial experience simple and efficient for both patients and providers in several ways. Let me provide a few examples.

First, patients can digitally view simple, modern and unified statements at the guarantor or family level across care settings. This is a critically unmet need in the market today. Second, patients receive coordinated tailor communications throughout their healthcare journey. These communications, which are driven by machine learning and adapted for patient preference keep the patient informed and in control of the financial spends [Phonetic]. Third, deep integrations with both health plans and HSA administrators offer a uniquely clear and align 360 degree view for patients. Fourth, patients receive financing options and anticipate their need for payment flexibility. Advanced machine learning creates personalized payment recommendations that work for each patient's unique needs, while improving provider revenue yield. And finally, with 10 years of curated data, from 300 million visits, we believe VisitPay has the most AI ready dataset for patient payment behavior, a vital differentiator as we think about our broader investments in digitization.

The patient satisfaction, loyalty, and retention, driven by VisitPay's platform are significant. Two of the most important outcomes are, a 40 point improvement in net promoter score, and a 35% improvement in patient cure, which is increasingly important, given the increase in patient payment mix over the past several years. By combining VisitPay's capabilities with R1, we expect to have the richest payment related functionality healthcare providers can offer their patients from pre-service through final bill resolution. We're excited about these capabilities, which will round out our PX offering to cover all patient access components, including integrated order and referral management, and real-time scheduling with booking and appointment, comprehensive pre-registration, pre-authorization and price estimation before patients arrive for their appointment, contactless check-in and digital pre-service forms when they arrive for the appointment, and seamless digitized bill visibility, and payment options pre-visit at the point of care, and post-visit, with visibility across care settings, and into their payment choices.

We expect to formally launch this comprehensive solution mid-year, and will showcase it at the HIMSS Conference in August, but we will also hold an investor event to highlight this, and other technology initiatives under way at R1. In addition to rounding out our PX platform, VisitPay allows us to establish a leading position in the consumer payments area. Healthcare consumer debt is arguably the largest and most inefficiently managed liability in our services cart. As we seek to solve high-value problems to create a competitive advantage for providers, we can't think of a better space for disruptive innovation. And we believe we will be rewarded well for our investments in this area. VisitPay will also advance our technology platform, with both access to a robust dataset to enhance our AI-based automation roadmap, and patient contact capabilities, which will enable us to reduce friction in the patient access and denials management domains. R1 will also gain substantial technical engineering talent as part of this acquisition, which accelerates our technology roadmap.

In addition to VisitPay's impressive stand-alone growth trajectory, we are also expecting meaningful costs synergies from the acquisition by deploying VisitPay's deep functionality across the 40 billion of NPR we have under management. Over time, we also see significant revenue synergies. I'll note our sales team is excited to communicate our enhanced end-to-end value proposition, since much of VisitPay's install base lies with Barge health systems similars our charter base of end-to-end customers.

In summary, the rationale for bringing together R1 and VisitPay's capabilities was very compelling, further fueling our conviction with the results at some of our common customers, where we've been able to generate value beyond what either company on a stand-alone basis would have been able to do. We believe these proof points are replicable across our customer base and a broad set of healthcare providers. Next, let me provide a customer update with a focus of the Ascension agreement and ongoing deployment activities, I would like to point.

I'm pleased to announce the strategic expansion of our revenue cycle services agreement with Ascension. This expansion can be broadly categorized into the following three areas. One, comprehensive deployment of our PX technology solution across the acute and ambulatory environments. Two, expansion of our schedule install, and certain patient facing services through our global delivery centers. And third, approval around a broader application of technology and use cases for automating key functions within our operations.

As noted in my first point, Ascension, will be standardizing its technology footprint for digital engagement, and will now utilize R1's complete PX technology solution for both the acute and ambulatory settings of care. Important to note, this technology expansion also includes the full suite of patient payment capabilities. In addition to the strategic expansion, we have extended our master services agreement with Ascension through April of 2031. We expect this expansion to be net favorable over the term of the agreement relative to our prior contract. In addition, the weighted average contract life for our end-to-end contracts is now nine years. This gives us a high degree of visibility, as we think about making long-term investments to support future growth.

Turning now to LifePoint. Onboarding continues to progress on schedule. We initiated Phase 1 onboarding in January, and from that Phase 2 enable. To-date, we have welcomed over 700 employees from LifePoint to R1, and technology integration for Phase 1 hospitals is currently under way. We expect to commence Phase 3 in July, with the goal of completing all deployment activities in mid-2022. On a related note, we are pleased to have welcome David Dill, LifePoint CEO and President to R1's Board, deepening our strategic partnership. This depth of healthcare expertise and broad vantage point will be invaluable to the company.

Next, I'd like to turn to our automation effort. We are highly committed to this effort, as it presents an opportunity to fundamentally transform the industry by reducing the latency and inefficiency that exists in the revenue cycle management infrastructure today. The 15 million tasks we automated by early 2020 delivered approximately $20 million in EBITDA benefit last year. We now have 40 million tasks in production, up from 30 million, as we exited 2020. These 10 million incremental tasks cover 8 new routines and demonstrate an accelerated development pace. The modular nature of our development approach allows us to develop new routines at a faster pace by reusing and adding to an existing automation.

Additionally, the investments we have made in additional core capabilities, beyond just RPA, including optical character recognition, natural language processing, expert rules and machine learning, workflow integration and analytics have expanded our automation coverage of any given workflow. In closing, we remain very excited about our business prospects going forward.

To recap the key messages from today's call. Our team continues to perform exceptionally well, and this is translating directly to our financial performance. With our Q1 results, we are off to a strong start for the year, and look forward to continued strong execution going forward. And market dynamics remain very favorable and we have a high degree of confidence in adding $4 billion NPR from new end-to-end deals in 2020. VisitPay rounds out our PX platform to be a market leading consumer payment platform, and establishes a leading position in the broader consumer payments ecosystem. Our expansion of the Ascension agreement is a meaningful validation of our PX technology solution, and the expansion is net favorable vis-a-vis our priority. We continue to invest heavily in automation, and the modular nature of our development approach allows us to develop new routines at a faster pace.

Now, I'd like to turn the call over to Rachel.

Rachel Wilson -- EVP, Chief Financial Officer & Treasurer

Thank you, Joe, and good morning, everyone. We're pleased to report strong first quarter results, with revenue of $342.6 million, up 6.9% year-over-year, and adjusted EBITDA of $80.4 million, up 30.5% year-over-year. Adjusted EBITDA margin for the quarter was 23.5%, up 430 basis points from 19.2% in Q1 2020, driven largely by significant higher incentive fees.

Reviewing the first quarter results in more detail. Net operating fees of $286.1 million increased 1.9% or $15.2 million year-over-year, primarily driven by revenue from new customers, and partially offset by anticipated COVID-related volume pressure. On a sequential quarterly basis, net operating fees increased $14.7 million, driven by continued recovery in patient volumes. Incentive fees of $29 million were up $12.2 million over the prior year, and $1.6 million sequentially, driven by strong operational execution.

Other revenue $27.5 million increased 20.6% or $4.7 million year-over-year, driven by contributions from SCI, which was somewhat offset by lower revenue physician advisory services due to COVID-related volume decline. The non-GAAP cost of services in Q1 was $242.8 million compared to $237.6 million last year, driven by costs associated with certain new customers, and onboarding LifePoint. Importantly, our automation digitization efforts continue to drive efficiencies, which helped the cost of services flat sequentially, down 330 basis points year-over-year. Non-GAAP SG&A expenses of $19.4 million were down almost 9% year-over-year, primarily due to lower travel and marketing costs as well as corporate cost control actions. On a sequential basis, SG&A costs decreased $3.4 million as Q4 results included $1.6 million in payroll taxes related to the vesting of employee stock awards. Adjusted EBITDA for the quarter was $80.4 million, up $18.8 million or 30.5% year-over-year. This increase was largely due to higher incentive fees further magnified by our automation and digitization efforts helping lower costs.

Lastly, we incurred $13 million in other costs in Q1 related to the rationalization of our real estate footprint, ongoing COVID-related expenses and costs associated with strategic initiatives, including the VisitPay acquisition and the capital structure simplification transaction, which we completed in January.

Turning to the balance sheet. Cash and cash equivalents at the end of March were $103.5 million compared to $173.8 million at the end of December. Use of cash in the quarter was largely due to $105 million payment for the conversion of preferred shares to common as well as capex of $9.6 million. We generated $46 million in cash from operations in Q1, driven by adjusted EBITDA growth in the quarter. We remain focused on generating strong cash flow from operations. And one of our focus areas this year is to carefully manage our AR days, which increased last year, primarily due to AR associated with the RevWorks and SCI acquisitions.

We also expect our other expense line to moderate excluding expenses related to M&A activities. Net debt at the end of March, inclusive of restricted cash was $444.1 million compared to $379.8 million at the end of December. The increase was driven by use of cash for the capital structure transactions. Available liquidity at the end of Q1 was in excess of $130 million consistent with commentary on the Q4 earnings call. We believe, our liquidity is sufficient to invest in and grow the business or navigating in current environment. In order to provide additional flexibility and to fund the VisitPay acquisition, we intend to refinance our current debt facilities, concurrent with the completion of the acquisition and expect improved liquidity and pricing as a result of the refinancing.

Turning to our financial outlook, we continue to expect revenue of $1.41 billion to $1.46 billion and adjusted EBITDA of $315 million to $330 million for 2021. We continue to assume the patient volumes to remain at 90% to 95% of pre-COVID level, inline with our experience year-to-date across our customer base. We expect to update our guidance after completion the VisitPay acquisition. R1 will acquire the business for approximately $300 million in cash and transaction that provides the tax benefit valued at approximately $40 million, equating to an effective purchase price of approximately $260 million.

To give you a sense of VisitPay financial profile, the growth is strong with greater than 70% compounded in annual revenue growth over the 2019 to 2021 period, and comes the very compelling gross margin profile. Beyond 2021, we expect VisitPay to be accretive to growth and margin. Consistent with my comments on our last call, we expect Q2 revenue in the range of $335 million to $345 million and adjusted EBITDA of $65 million to $75 million. As previously noted, the anticipated sequential decline in adjusted EBITDA is largely a function of upfront costs associated with onboarding the LifePoint contract.

Before I conclude, I want to briefly touch on our ESG initiative. We published our inaugural ESG report in March and we are pleased to have received a lot of positive support and feedback. We'd like to enhancing the interest of all of our stakeholders through our ESG commitments that are centered on innovation, integrity and inclusion. Our report can be viewed at r1rcm.com/esg and as always we welcome your perspectives.

In closing, I'm pleased with our continued execution that delivered Q1 results ahead of our expectations. The fundamentals of our business remain strong and we look forward to maintaining the momentum demonstrated in Q1 as the year progresses.

Now, I'll turn the call over to the operator for Q&A. Operator?

Questions and Answers:

Operator

[Operator Instructions] Your first question comes from the line of Sean Dodge with RBC Capital Markets.

Sean Dodge -- RBC Capital Markets -- Analyst

Thanks. Good morning and congratulations on the quarter. On the revenue outlook, Joe, you mentioned high degree of confidence in your NPR target. Maybe digging into that a little bit more, you've said before you've been very active on the RFP front, including a handful of several large one. Can you give us a sense of how those are progressing? Are all of them still active, had some been decided now? And then maybe anything else you can kind of share about sales pipeline, sales outlook? And how we should think about you hitting that $4 billion over the coming quarters?

Joseph Flanagan -- President & Chief Executive Officer

Yeah, thanks, Sean. Just a couple of comments to provide additional color on progression of pipeline. The first thing is, I would say, linking to your question, I would say, yes, the RFP activity is active and we are progressing that nicely through the different phases of the pursuit process -- commercial pursuit process. The second thing I would say is, our in total active end-to-end pipeline is up 175% since the start of the year. So, we're also seeing -- we're seeing active opportunities progress to later stages, which underpins some of our view on the year. And then in totality on end-to-end basis, we're seeing the total pipeline in aggregate grow nicely. So, we continue to feel really good about the end-to-end offering and end market receptivity and we're seeing that across the board in that overall commercial pipeline dimensioning.

In addition to that and I think another indicator of the flexibility we have in our offerings, we booked 24 new modular agreements with new customers in Q1 and the overall revenue bookings was 74% ahead of our internal target. So, we continue to see just broad-based positive activity at the end market and that's some of the dimension that I'd show you, Sean.

Sean Dodge -- RBC Capital Markets -- Analyst

Okay, great. And then maybe along the lines of what you just announced here with Ascension and the complete adoption there now of your PX solution. If we think about the cross-selling opportunity across the other parts of your current base, can you give us an idea of what proportion is currently using all the components of your PX platform? Maybe just kind of how we should be thinking about the size, the potential around cross-selling into the other parts of that kind of non-Ascension base?

Joseph Flanagan -- President & Chief Executive Officer

Right. Yeah, the way I would describe that is with our two probably most mature deployments that being Ascension and Intermountain. And Ascension and Intermountain have a little bit different strategies as it relates to their visual intake, but we're pretty penetrated with this announcement on Ascension across those two customer basis. There are some opportunities on the edge, but what I would really point to is the book of business outside of those two anchor customers obviously LifePoint, Quorum, Amida, Rush, Penn State, etc., and there are significant white space for us to expand into. And as I said, increasingly, our goal is seamless integration across care settings. So that's ambulatory acute and increasingly based on our development roadmaps post-acute setting.

And then as well as seamless integration across the workflow, what I mean by in terms of workflow that the order intake, the referral process, scheduling signals, financial clearance, i.e., the registration or create etc., that process, and then finally the payment process. So that overall value prop is resonating. And we see strong receptivity to that in our captive end-to-end customers.

Sean Dodge -- RBC Capital Markets -- Analyst

Okay, that's very helpful. Thank, again.

Joseph Flanagan -- President & Chief Executive Officer

Great. Thanks, Sean.

Operator

Your next question comes from the line of Donald Hooker with KeyBanc.

Donald Hooker -- KeyBanc -- Analyst

Great. Good morning. I understand the acquisition of VisitPay, but I was curious if you all could provide any detail on VisitPay's financials itself? Like what exactly are you acquiring financially? It's the company that will kind of -- what kind of revenue should we start building in? And EBITDA -- is there other large EBITDA losses, can you elaborate on some of the financials of the company that you're occurring?

Joseph Flanagan -- President & Chief Executive Officer

Yeah, what I would say, Don, is I'll just use the full year basis. So, we look to -- if we look to 2022, we would expect this business to do about $41 million, $42 million in revenue, and we would expect it to contribute conservatively $7 million to $8 million in EBITDA. As Rachel mentioned in her commentary, this business has been growing at 70% compounded over the trailing three years. So it's not a very high growth profile, and it's got a very compelling gross margin rate, that comes with that growth.

But, maybe equally important, there are significant, what I'll call, captive operational synergies. And what I mean by that is, that's where we're not dependent on the external markets for growth. We're just to a large degree in control of fully deploying the VisitPay platform across our contracted book of business. And those synergies come in the form of digitizing interface with the patients around the payment process, which allows us to lower our cost structure.

The second thing is, improving the yield, which contributes to our KPIs. And the third thing is, we think over time, we will be able to materially shift on to the VisitPay platform digitized statements, or online bill presentation. And today, we have a significant amount of cost that still exists in print statement operations. Somewhat tactical, but it's without a doubt, from our standpoint, a synergy that we have a high degree of confidence in. The collective both of that is probably are maturity more than twice in the pace 2022 contributed with us. So when we roll all that in, not even counting for net new growth, we think we can go get -- we think on a synergized basis with only assuming our operating control synergies this is a very accretive transaction for us.

Donald Hooker -- KeyBanc -- Analyst

Got you.

Joseph Flanagan -- President & Chief Executive Officer

It's a very strategic technology capability in the eyes of the end market.

Donald Hooker -- KeyBanc -- Analyst

Got you. I mean, just to be clear, so there is the synergies, which make a ton of sense that will probably phase into your P&L over the next few years. And then if -- just on a stand-alone basis, you're saying $41 million, $42 million of revenue next year, obviously, high growth. I mean, just to be clear from what...

Joseph Flanagan -- President & Chief Executive Officer

We are growing at 70% trailing. That growth will come in as the business grows. But it's still in any scenario going to be, from our standpoint, looking out past 2022 off of that basis a very high growth business, and very high margin business.

Donald Hooker -- KeyBanc -- Analyst

Sure. And then maybe just as a follow-up, also would love to hear -- I mean, VisitPay has been around for a while. I think I'm just looking at their -- not familiar with them obviously. But it looks like they have some nice logos on their website of different health systems they work with, some of which are RCM's clients, and some of which are not. Can you just talk about kind of any maybe client introductions or kind of overlap or what their client base looks like?

Joseph Flanagan -- President & Chief Executive Officer

Yeah. One of the things that -- as we looked at the different targets in the patient payment ecosystem, one of the things we really liked about VisitPay's platform, is they've actually served some of the most sophisticated health systems, and you can see that in their logos, as you referenced on. And from our vantage point, that's a really important capability -- demonstrated capability that we like about their profile. We know how hard it is to serve some of the leading health systems. And those are health systems that are run very, very well. So when you see a technology that's driving incremental improvement, whether that be in the patient experience, or in the financial outcomes that is a true proof point from our standpoint to the leading position that VisitPay has.

That's the first point. The second point is, right after this call, we've got probably 20 calls with prospects, meaning not current customers. We're really excited to introduce this acquisition, talk with those potential net new customers about the enhanced value prop we're bringing to the market. And that's an indication, Don, of some of the growth synergies that in my prior comments, I didn't even include. But we do think there is potential over time for those to be significant, and potentially outweigh the captive operational synergies that we used in our underwriting case.

Donald Hooker -- KeyBanc -- Analyst

Great. Well, sounds interesting. Good luck, and thanks for taking my question.

Joseph Flanagan -- President & Chief Executive Officer

Thank you, Don.

Operator

Your next question comes from the line of Stephanie Davis with SVB Leerink.

Stephanie Davis -- SV8 Leerink -- Analyst

Hey, guys. I echo my congrats on a very busy quarter.

Joseph Flanagan -- President & Chief Executive Officer

Thanks, Stephanie.

Stephanie Davis -- SV8 Leerink -- Analyst

Following on the last question, I was hoping to hear about how you chose VisitPay among the many payment providers in the Health tech universe. And just, given some of your prior investments on the patient experience platform, what nudged you closer to buy over build?

Joseph Flanagan -- President & Chief Executive Officer

Yes. One of the things -- as I mentioned, one of the factors for us choosing VisitPay was, they have demonstrated value prop into our target customers. So again, that was without a doubt a factor in terms of our calculus. The second thing is, we have had an opportunity over the past couple of years to have a part buy-sell partnership with VisitPay. Now, what I'll say is, we have not taken full advantage of that, just because of all the priorities that we've had ongoing around deploying then growth and absorbing those things, but we know via that partnership, we saw a firsthand the results that we could generate.

The third thing is, as we got into deeper discussions with VisitPay, we were really, really impressed with the human capital, or the talent they have in the company. And I would particularly emphasize along the following three lines. Their growth, their sales team, and their channel for growth. The second thing is their marketing and some of the commercialization and productization skills that they have. And then finally, and most importantly, with the technology development profile. And so, talent was a big factor for us.

And then the third and final thing is, really just on the advanced analytics and algorithms they have around serving the patient with very tailored financing options, and we think that's a key differentiator above and beyond just a bill presentation platform, which obviously is very, very important. But at the end of the day, those deep insights and the analytics that they've built over the past 10 years, we think are compelling and differentiated to their peers.

Stephanie Davis -- SV8 Leerink -- Analyst

Understood. So, kind of adds to your PX development capabilities going forward as well.

Joseph Flanagan -- President & Chief Executive Officer

Yeah. I don't think -- I think we're in really good shape from depth of capability in every one of the workflow steps, where our call it organic investments have been, and are going to continue to be are around the deep integration across the process flows. So, across that workflow continuum and deep development work to ensure we seamlessly integrate across care settings. So, I mentioned ambulatory and acute. That was a big strategic driver in our discussions with the Ascension.

And then, I would say, looking forward, we anticipate making significant investments organically via our technology teams around extending that workflow continuum into the post-acute setting of care, which we think there is a significant opportunity. And then the final thing is, from our standpoint off of the PX platform, we think there is a very logical extension of some of these services to better serve the clinician or the provider. So, those are some areas on our internal development roadmap looking forward that we're very focused on.

Stephanie Davis -- SV8 Leerink -- Analyst

Just one last follow-up for me. Just given this acquisition and the extended extension contract, how does it change your relationship with Phreesia, if at all? And you know that Ascension is still interested in expanding the hardware component, given kind of the changing views on that with COVID?

Joseph Flanagan -- President & Chief Executive Officer

Yes. I really don't want to get into -- it wouldn't be -- what's been my perspective to get into Ascension strategies from an IT standpoint of hardware. But I would -- what I would say is, we're very focused on solving a very complicated problem, which is and I'll keep referencing this the integration -- the seamless integration in the eyes of the patients across care settings, and across workflow. And for us to solve that problem, we have to go very deep on the integration of technology, and that underpins kind of all of our bias and our actions.

Now, there will be different personas of customers, and there will be customers that don't necessarily want to embark, or they're not prepared at this point in time to embark on that journey, and they just need a very compartmentalized solution set. So I think our focus -- and what I would draw your attention to is, our focus is along those lines, and we feel, and we're hearing from our current customers as well as target customers, who by our own ambition are of the larger kind of integrated health systems that they really would like us to bring that value prop to the market. So that's where our internal efforts lie, which is just maybe not the same end market as some of the intake companies.

Stephanie Davis -- SV8 Leerink -- Analyst

That is a super helpful clarification. Thank you, and congrats again.

Joseph Flanagan -- President & Chief Executive Officer

Thanks, Stephanie.

Operator

There are no further questions at this time. I would now like to turn the conference back to Joe Flanagan. We do have a question, I'm sorry.

Joseph Flanagan -- President & Chief Executive Officer

Go ahead, please.

Gene Mannheimer -- Colliers Securities -- Analyst

Thanks, Joe. Good morning everybody, and congrats on this quarter. Did you talk about the client overlap with VisitPay, in particular, maybe quantifying the market opportunity of cross selling into your base and vice versa, maybe RCM into their base? And up to this point, do you have any of your own patients functionality that maybe is going to be replaced, either self developed with your script library, or are your customers generally using third party applications for this function now? Thank you.

Joseph Flanagan -- President & Chief Executive Officer

Yeah. So, let me first cover -- just give a little bit more color on client overlap, VisitPay serves Intermountain. So we work with them in that setting. And as I mentioned before, they're partially deployed at Ascension. We will fully deploy the platform at Ascension. And then, in our captive book of business, outside of those two anchor clients, there is significant white space for us to deploy. Now, as part of that deployment, we will be displacing third party patient payment platforms that exist in that third party spend that -- with our contractual frameworks and transition to our control. And that's very much in line with comments that I had in the past, where we have an internal technology platform, and we have very broad coverage of the process with our captive technology. We displace and insource, integrate and simplify for our customers their technology ecosystem, and that will occur with VisitPay.

If you look at this outside of primarily Intermountain, and you can see some of their logos on their website, whether that be a Innova, Carilion Clinic, Geisinger, Henry Ford you start to get a sense that, from our standpoint, they've done the hard work of trying to penetrate the leading integrated delivery systems, and that's squarely in our strategic focus from a growth standpoint. It's early innings, we're just starting a process. But I'm generally optimistic that those discussions will receive well, and we'll have a lot of focus from our commercial teams to curate those relationships, and look to convey the value on a broader basis that we can deliver via partnership. So that's how I would characterize Gene kind of the spectrum, I'll call it install base, and client potential synergy.

Gene Mannheimer -- Colliers Securities -- Analyst

Pretty helpful. Thank you.

Joseph Flanagan -- President & Chief Executive Officer

Thanks, Gene. Heggie, if we don't have any more questions, just thank you for your help today in moderating the call, and thanks everybody for joining us today. We are very excited about the developments that we're announcing, and look forward to updating you on progress on an ongoing basis in future calls. Thanks again for all your participation.

Operator

[Operator Closing Remarks]

Duration: 43 minutes

Call participants:

Atif Rahim -- Senior Vice President, Investor Relations & Business Development

Joseph Flanagan -- President & Chief Executive Officer

Rachel Wilson -- EVP, Chief Financial Officer & Treasurer

Sean Dodge -- RBC Capital Markets -- Analyst

Donald Hooker -- KeyBanc -- Analyst

Stephanie Davis -- SV8 Leerink -- Analyst

Gene Mannheimer -- Colliers Securities -- Analyst

More RCM analysis

All earnings call transcripts

AlphaStreet Logo

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.